Table 2.
Characteristics of participants with breast cancer (N = 173).
| N (%) | |
|---|---|
| Cancer Stage | |
| 0 | 27 (15.6) |
| I | 75 (43.4) |
| II | 55 (31.8) |
| III | 16 (9.2) |
| Tumor Histology | |
| Hormone Positive, HER2- | 110 (63.6) |
| Hormone Positive, HER2+ | 15 (8.7) |
| Hormone Positive, HER2 Unknown | 18 (10.4) |
| Hormone Negative, HER2- (Triple Negative) | 15 (8.7) |
| Hormone Negative, HER2+ | 9 (5.2) |
| Hormone Negative, HER2 Unknown | 2 (1.2) |
| Not Tested | 4 (2.3) |
| Treatment for Breast Cancer (in addition to Surgerya) | |
| Chemotherapy Only | 18 (10.4) |
| Radiation Only | 64 (37.0) |
| Chemotherapy and Radiation | 55 (31.8) |
| None of the Above (Surgery Only) | 36 (20.8) |
| Hormonal Inhibition Therapyb | |
| Yes | 124 (72.1) |
| No | 48 (27.9) |
| Timing of First Post-Treatment Visit, by Treatment (in addition to Surgery) | Median Days (Interquartile Range) |
|
|---|---|---|
| Since End of Treatment | Since Baseline Visit | |
| Chemotherapy Only | 36 (21–65) | 215 (175–261) |
| Radiation Only | 28.5 (13–50) | 135 (103–183) |
| Chemotherapy and Radiation | 30 (13–53) | 268 (240–300) |
| None of the Above (Surgery Only) | 75 (38.5–100) | 92.5 (59–122) |
a
All participants with breast cancer underwent surgery for their disease.
b
When prescribed, hormonal inhibition therapy was in use at the 1-Year visit and continued through the 2-Year visit. Data on this therapy were missing for 1 patient.